FDA proposes withdrawal of approval for Salerno's Flolipid suspension
The FDA's Center for Drug Evaluation and Research proposes to withdraw approval of NDA 206679 for Flolipid suspension 20 mg/5 mL and 40 mg/5 mL because Salerno Pharmaceuticals has repeatedly failed to file required annual reports. Salerno may request a hearing on the proposal.
Primary source
Federal Register notice, November 18, 2026
Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing
Machine-summarized from the source above; not independently reported. How we use automation